Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients

Transfusion ◽  
2016 ◽  
Vol 56 (6) ◽  
pp. 1402-1405 ◽  
Author(s):  
Ashley Teusink ◽  
Susan Pinkard ◽  
Stella Davies ◽  
Mark Mueller ◽  
Sonata Jodele
Keyword(s):  
Stem Cells ◽  
Peripheral Blood ◽  
Pediatric Patients ◽  
Peripheral Blood Stem Cells ◽  
Blood Stem Cells

Evaluation of the Fresenius cell separator AS 104 for harvesting peripheral blood stem cells in pediatric patients

1994 ◽  
Vol 15 (1) ◽  
pp. 93-99 ◽  
Author(s):  
Kurt Leibundgut ◽  
Joseph Muff ◽  
Andreas Hirt ◽  
Heike Mitschulat ◽  
Urs E. Nydegger ◽  
...  
Keyword(s):  
Stem Cells ◽  
Peripheral Blood ◽  
Pediatric Patients ◽  
Peripheral Blood Stem Cells ◽  
Cell Separator ◽  
Blood Stem Cells

scholarly journals Safety and Efficacy of Plerixafor for Mobilization of Peripheral Blood Stem Cells in Pediatric Patients

2014 ◽  
Vol 20 (2) ◽  
pp. S294-S295 ◽  
Author(s):  
Ashley Teusink ◽  
Sue L. Pinkard ◽  
Stella M. Davies ◽  
Mark Mueller ◽  
Sonata Jodele
Keyword(s):  
Stem Cells ◽  
Peripheral Blood ◽  
Pediatric Patients ◽  
Peripheral Blood Stem Cells ◽  
Safety And Efficacy ◽  
Blood Stem Cells

scholarly journals Small Split Doses of CD34+Peripheral Blood Stem Cells to Support Repeated Cycles of Nonmyeloablative Chemotherapy

2017 ◽  
Vol 2017 ◽  
pp. 1-4 ◽  
Author(s):  
Maxim Yankelevich ◽  
Sureyya Savasan ◽  
Igor Dolgopolov ◽  
Roland Chu ◽  
George Mentkevich
Keyword(s):  
Stem Cells ◽  
High Risk ◽  
Peripheral Blood ◽  
Pediatric Patients ◽  
Case Series ◽  
Limiting Factor ◽  
Peripheral Blood Stem Cells ◽  
Platelet Recovery ◽  
Solid Malignancies ◽  
Blood Stem Cells

Cumulative myelosuppression is the main limiting factor for administration of repeated cycles of chemotherapy. We present a case series of five pediatric patients with high-risk solid malignancies who received small split peripheral blood stem cells (PBSC) doses of less than 1 × 106/kg CD34+cells obtained after a single leukapheresis procedure and given after repeated cycles of ICE (ifosfamide, carboplatin, and etoposide) chemotherapy. Mean duration to absolute neutrophil count (ANC) recovery to >1000/mm3and platelet recovery to >50 × 103/mm3was 17.1 and 24.3 days. Using split doses of PBSC prevented prolonged neutropenia after repeated cycles of submyeloablative chemotherapy.

CLINICAL COLLECTION AND USE OF PERIPHERAL BLOOD STEM CELLS IN PEDIATRIC PATIENTS

1989 ◽  
Vol 47 (4) ◽  
pp. 613-616 ◽  
Author(s):  
LARRY C. LASKY ◽  
BRUCE BOSTROM ◽  
JUDITH SMITH ◽  
THOMAS J. MOSS ◽  
NORMA K. C. RAMSAY
Keyword(s):  
Stem Cells ◽  
Peripheral Blood ◽  
Pediatric Patients ◽  
Peripheral Blood Stem Cells ◽  
Blood Stem Cells

Mobilization and Harvesting of Peripheral Blood Stem Cells in Pediatric Patients With Solid Tumors

2011 ◽  
Vol 15 (6) ◽  
pp. 579-586 ◽  
Author(s):  
Dobrila Veljkovic ◽  
Dragana Vujic ◽  
Olivera Serbic Nonkovic ◽  
Dragana Jevtic ◽  
Zeljko Zecevic ◽  
...  
Keyword(s):  
Stem Cells ◽  
Solid Tumors ◽  
Peripheral Blood ◽  
Pediatric Patients ◽  
Peripheral Blood Stem Cells ◽  
Blood Stem Cells
Sign in / Sign up

Export Citation Format

Share Document